Evidence map›Paper›PMID 39582973›Full record

ArticleFrontiers in medicine2024

Case report: STRN3-NTRK3 fusion in uterine sarcoma with spleen metastasis: a new variant in the spectrum of NTRK-rearranged tumors.

Piergiuseppe Colombo, Giuseppina Adriana Buonamassa, Anita Giulianini, Letizia Hassan, Noemi Rudini, Antonio Rizzo, Enrico Cavallo, Carlo Carnaghi, Salumeh Goudarzi, Sebastiano Mongiovì and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Piergiuseppe ColomboDepartment of Biomedical Science, Humanitas University, Milan, Italy.
Giuseppina Adriana BuonamassaDepartment of Biomedical Science, Humanitas University, Milan, Italy.
Anita GiulianiniDepartment of Biomedical Science, Humanitas University, Milan, Italy.
Letizia HassanDepartment of Biomedical Science, Humanitas University, Milan, Italy.
Noemi RudiniDepartment of Pathology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Antonio RizzoDepartment of Pathology, Humanitas Istituto Clinico Catanese, Catania, Italy.
Enrico CavalloDepartment of Pathology, Humanitas Istituto Clinico Catanese, Catania, Italy.
Carlo CarnaghiDepartment of Medical Oncology, Humanitas Istituto Clinico Catanese, Catania, Italy.
Salumeh GoudarziDepartment of Radiology, Humanitas Istituto Clinico Catanese, Catania, Italy.
Sebastiano MongiovìDepartment of Surgery, Humanitas Istituto Clinico Catanese, Catania, Italy.
Sarah PafumiDepartment of Medical Oncology, Humanitas Istituto Clinico Catanese, Catania, Italy.
Stefano MarlettaDepartment of Pathology, Humanitas Istituto Clinico Catanese, Catania, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurotrophic tyrosine receptor kinase (NTRK) fusions are infrequent genetic events that can occur in various tumor types. Specifically, NTRK-rearranged sarcoma has been observed in pediatric mesenchymal tumors and, to a lesser extent, in adult mesenchymal tumors like fibrosarcoma. Recently, NTRK-rearranged uterine sarcoma (US) has been identified as a rare entity characterized by constitutive activation or overexpression of the TRK receptor, which plays a role in cell proliferation and differentiation. Since its initial description in 2018, only 46 cases of NTRK-rearranged US have been reported. In this context, herein we describe an exceptional case of an

Indexed as

neurotrophic tyrosine receptor kinase (NTRK)rearranged tumorsSTRN3-NTRK3targeted therapyuterine sarcoma

Identifiers

PMID39582973
PMCPMC11581886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.